The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Cardiff Oncology Inc shares valued at $14,905 were purchased by Levine James E. on Dec 17 ’24. At $5.42 per share, Levine James E. acquired 2,752 shares. The insider’s holdings grew to 65,316 shares worth approximately $0.26 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Levine James E. purchased 2,400 shares, netting a total of over 12,000 in proceeds. Following the buying of shares at $5.00 each, the insider now holds 67,716 shares.
Before that, Levine James E. had added 2,564 shares to its account. In a trade valued at $9,820, the Chief Financial Officer bought Cardiff Oncology Inc shares for $3.83 each. Upon closing the transaction, the insider’s holdings increased to 2,564 shares, worth approximately $0.25 million.
As published in their initiating research note from Craig Hallum on September 06, 2024, Cardiff Oncology Inc [CRDF] has been a Buy and the price target has been revised to $8. Analysts at William Blair started covering the stock with ‘”an Outperform”‘ outlook in a report released in early January. As of December 08, 2021, Robert W. Baird has initiated its “an Outperform” rating for CRDF.
Analyzing CRDF Stock Performance
During the last five days, there has been a drop of approximately -27.48%. Over the course of the year, Cardiff Oncology Inc shares have jumped approximately 162.16%. Shares of the company reached a 52-week high of $6.42 on 03/25/24 and a 52-week low of $1.44 on 02/05/24. A 50-day SMA is recorded $3.14, while a 200-day SMA reached $3.20. Nevertheless, trading volume fell to 0.94 million shares from 1.43 million shares the previous day.
Support And Resistance Levels for Cardiff Oncology Inc (CRDF)
According to the 24-hour chart, there is a support level at 3.75, which, if violated, would cause prices to drop to 3.57. In the upper region, resistance lies at 4.17. The next price resistance is at 4.41. RSI (Relative Strength Index) is 54.97 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.34, which suggests the price will decrease in the coming days. Percent R is at 50.88%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
Which companies own the most shares of Cardiff Oncology Inc (CRDF)?
On October 22, 2020, H.C. Wainwright assigned a price target of “a Buy” to the stock and initiated coverage with a $27.
